Intraoperative Radiotherapy After the Resection of Brain Metastases - a Phase II Feasibility Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Brain Metastases
- Sponsor
- Universitätsmedizin Mannheim
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Median local progression-free-survival
- Last Updated
- 3 years ago
Overview
Brief Summary
INTRAMET examines prospectively the effectiveness of an intraoperative radiotherapy immediate after the surgical resection of brain metastases. Patients won't receive further radiation therapy of the intraoperatively treated lesion.
Detailed Description
Brain metastases occur in up to 40% of all patients diagnosed with systemic cancer. Without adjuvant radiotherapy after resection of space occupying lesions local recurrence rates are high. That is why guidelines recommend a cavity boosting with x-rays. External beam radiotherapy can lower the risk of local recurrence but means longer hospitalization, prolongs the time to systemic salvage therapies and bears risks of radionecrosis and leucoencephalopathy with neurological and cognitive decline. A solution for this problem could be onetime intraoperative radiotherapy (IORT) with soft x-rays to sterilize the resection cavity, which may provide both: freedom from local recurrence fast track salvage therapy initiation. INTRAMET is a single institution, open-label, prospective, phase 2 feasibility study for intraoperative radiotherapy immediately following resection of brain metastases. 50 adult patients with resectable not dural brain metastases should be treated in surgery after tumor resection with IORT with 20-30Gy prescribed to the margin of the resection cavity. The highest dose tolerable to surrounding risk structures (N. opticus, brainstem) should be used. With this method, the investigators hope to show similar local control rates to postoperative external beam radiotherapy in line with guideline recommendations with less patient hospitalization and faster start of rescue therapies which could lead to a favorable overall outcome and less cognitive side effects.
Investigators
Stefanie Brehmer
MD
Universitätsmedizin Mannheim
Eligibility Criteria
Inclusion Criteria
- •Karnofsky Performance index ≥ 50%
- •MRI T1 Gadolinium enhancing non-dural resectable lesion
- •Informed consent
- •Adequate birth control
- •Frozen section confirms metastasis
- •Adequate distance to optic nerve and brainstem
Exclusion Criteria
- •Dural lesions or meningeal carcinomatosis
- •Frozen section reveals glioma, lymphoma,small cell lung cancer or germinoma
- •Psychiatric or social condition interfering compliance
- •Contraindication against anesthesia, surgery, MRI and/or Gadolinium
- •Pregnant or breast-feeding women
Outcomes
Primary Outcomes
Median local progression-free-survival
Time Frame: 2 years
Rate of recurrence of the treated lesion in the brain
Secondary Outcomes
- Time to further therapy(6 month)
- Patients cognitive performance(5 years)
- Overall-survival(5 years)
- Regional progression-free-survival(2 years)
- Patients quality of life(5 years)
- Intraoperative radiotherapy caused dose-limiting toxicities(6 month after intervention)
- Global progression-free-survival(2 years)